ClinicalTrials.gg
CompletedNCT02112526Updated Dec 20, 2024Results posted

Acalabrutinib (ACP-196), a Btk Inhibitor, for Treatment of de Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell Lymphoma

A Phase 1 interventional study of Acalabrutinib in Activated B-cell Diffuse Large B-Cell Lymphoma (ABC DLBCL), sponsored by Acerta Pharma BV. Completed at 7 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-12-20.

Sponsored by Acerta Pharma BV (part of AstraZeneca) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
21
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies testing acalabrutinib in Lymphoma, Large B-Cell, Diffuse — 5 open to participants now, 12 under way, 2 of them phase 3. acalabrutinib · Lymphoma, Large B-Cell, Diffuse.

Enrollment
14th of 15
21 · median 72
Started
2014
the only one that year
Phase 1
Only one
of the 15
Registered
1st of 15
by date
Lead sponsor
2 of 15
Acerta Pharma BV

Among the 15 studies testing acalabrutinib in Lymphoma, Large B-Cell, Diffuse, this one is the 14th largest by enrollment, is the only one that started in 2014, is the only one in phase 1, and was the 1st registered.

Lymphoma, Large B-Cell, Diffuse

1,872 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.

Browse Lymphoma, Large B-Cell, Diffuse studies →

Open to participants now

5 of the 15 studies testing acalabrutinib in Lymphoma, Large B-Cell, Diffuse are open now, in 6 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About acalabrutinib

acalabrutinib: first FDA approval 2017 (CALQUENCE), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 266 Lymphoma, Large B-Cell, Diffuse studies recruiting now, 177 (67%) set no upper age limit and 51 (19%) stop at 75 or younger; 25 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies testing acalabrutinib in Lymphoma, Large B-Cell, Diffuse, or all of them as a file.
02

Study summary

To characterize the safety profile of acalabrutinib in subjects with relapsed or refractory de Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell Lymphoma (DLBCL).

03

Conditions studied

  • Activated B-cell Diffuse Large B-Cell Lymphoma (ABC DLBCL)

Keywords

  • de Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell Lymphoma
  • Diffuse Large B-Cell Lymphoma
  • de Novo Activated B-cell (ABC)
  • de Novo Activated B-cell
  • ABC DLBCL
  • DLBCL
  • Lymphoma
  • B-Cell
  • Immunoproliferative Disorders
  • Immune System Diseases
  • Bruton's tyrosine kinase
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men and women ≥ 18 years of age.
  • confirmed de novo ABC DLBCL
  • disease
  • Subjects must have ≥ 1 sites

Exclusion criteria

Exclusion Criteria:

  • A life-threatening illness, medical condition or organ system dysfunction which, in the investigator's opinion, could compromise the subject's safety, interfere with the absorption or metabolism of acalabrutinib, or put the study outcomes at undue risk
  • Significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 6 months of screening, or any Class 3 or 4 cardiac disease as defined by the Functional Classification, or \< 50%
  • Malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel or ulcerative colitis, symptomatic inflammatory bowel disease, or partial or complete bowel obstruction.
  • Breast feeding or pregnant
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
21 participants (actual)

Study arms

  • Experimental
    Acalabrutinib

    Drug: Acalabrutinib

Interventions

06

What researchers measure

Primary outcomes

  1. Safety Profile of Acalabrutinib in Subjects With Relapsed or Refractory ABC DLBCL.

    Safety assessments included SAEs TEAEs, including AEs leading to discontinuation of study drug or dose reduction.

    Time frame: SAEs collected from time of consent; TEAEs beginning after first dose and continuing through 30 days (+/- 7 days) after last dose.

Secondary outcomes

  1. Area Under the Plasma Concentration (AUC)

    To Characterize the Pharmacokinetic parameter AUC of acalabrutinib

    Time frame: 1 Cycle (28 days)

  2. Maximum Observed Plasma Concentration (Cmax)

    To Characterize the Pharmacokinetic parameter Cmax of acalabrutinib

    Time frame: 1 Cycle (28 days)

  3. Evaluate Pharmacodynamic (PD) Effects (Done at US Sites Only)

    To evaluate the concentration pharmacodynamic effects of acalabrutinib

    Time frame: 2 Cycles (1 cycle = 28 days) and at end of treatment

  4. Evaluate Activity of Acalabrutinib as Measured by Overall Response Rate (ORR)

    To evaluate the activity of acalabrutinib as measured by ORR

    Time frame: From enrollment to the date of disease progression, assessed up to Cycle 48 (1 cycle is 28 days)

07

Results

Posted Jul 29, 2020

Participant flow

Participant flow — Overall Study
MilestoneCohort 1 - Relapse SubjectsCohort 2 - Refractory Subjects
Started1110
Enrolled1110
Received study medication1110
Discontinued study119
Subjects continuing study medication01
Completed01
Not completed119

Outcome measures

PrimarySafety Profile of Acalabrutinib in Subjects With Relapsed or Refractory ABC DLBCL.

Safety assessments included SAEs TEAEs, including AEs leading to discontinuation of study drug or dose reduction.

Time frame:
SAEs collected from time of consent; TEAEs beginning after first dose and continuing through 30 days (+/- 7 days) after last dose.
Reported as:
Count of participants · Participants
Safety Profile of Acalabrutinib in Subjects With Relapsed or Refractory ABC DLBCL.
ParticipantsCohort 1 - Relapse SubjectsCohort 2 - Refractory Subjects
Safety Profile of Acalabrutinib in Subjects With Relapsed or Refractory ABC DLBCL.32
SecondaryArea Under the Plasma Concentration (AUC)

To Characterize the Pharmacokinetic parameter AUC of acalabrutinib

Time frame:
1 Cycle (28 days)

Results for this outcome have not been posted.

SecondaryMaximum Observed Plasma Concentration (Cmax)

To Characterize the Pharmacokinetic parameter Cmax of acalabrutinib

Time frame:
1 Cycle (28 days)

Results for this outcome have not been posted.

SecondaryEvaluate Pharmacodynamic (PD) Effects (Done at US Sites Only)

To evaluate the concentration pharmacodynamic effects of acalabrutinib

Time frame:
2 Cycles (1 cycle = 28 days) and at end of treatment

Results for this outcome have not been posted.

SecondaryEvaluate Activity of Acalabrutinib as Measured by Overall Response Rate (ORR)

To evaluate the activity of acalabrutinib as measured by ORR

Time frame:
From enrollment to the date of disease progression, assessed up to Cycle 48 (1 cycle is 28 days)

Results for this outcome have not been posted.

Adverse events

Collected over Reported Adverse Events (AEs) include events starting on or after Day 0 and on or before Day 697. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 1 - Relapse Subjects3/11 (27.3%)4/11 (36.4%)10/11 (90.9%)
Cohort 2 - Refractory Subjects5/10 (50%)5/10 (50%)10/10 (100%)
Most frequent serious events
Showing 10 of 12
Most frequent serious events
EventCohort 1 - Relapse SubjectsCohort 2 - Refractory Subjects
Abdominal painGastrointestinal disorders0/112/10
PyrexiaGeneral disorders1/111/10
FatigueGeneral disorders0/111/10
PneumoniaInfections and infestations0/111/10
Viral infectionInfections and infestations0/111/10
Decreased appetiteMetabolism and nutrition disorders0/111/10
Respiratory failureRespiratory, thoracic and mediastinal disorders1/111/10
Skin necrosisSkin and subcutaneous tissue disorders0/111/10
Disease progressionGeneral disorders1/110/10
Septic shockInfections and infestations1/110/10
Most frequent other events
Showing 10 of 104
Most frequent other events
EventCohort 1 - Relapse SubjectsCohort 2 - Refractory Subjects
DiarrhoeaGastrointestinal disorders8/111/10
DizzinessNervous system disorders5/111/10
AnaemiaBlood and lymphatic system disorders2/114/10
FatigueGeneral disorders4/114/10
ConstipationGastrointestinal disorders4/110/10
NauseaGastrointestinal disorders2/113/10
CoughRespiratory, thoracic and mediastinal disorders3/113/10
HeadacheNervous system disorders3/112/10
VomitingGastrointestinal disorders0/112/10
Oedema peripheralGeneral disorders2/112/10

Baseline characteristics

Age, Continuous
Age, Continuous(Year)Cohort 1 - Relapse SubjectsCohort 2 - Refractory SubjectsTotal
Mean70.7 ± 9.5756.9 ± 16.2664.1 ± 14.66
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1 - Relapse SubjectsCohort 2 - Refractory SubjectsTotal
Female6511
Male5510
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cohort 1 - Relapse SubjectsCohort 2 - Refractory SubjectsTotal
Hispanic or Latino112
Not Hispanic or Latino10919
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohort 1 - Relapse SubjectsCohort 2 - Refractory SubjectsTotal
American Indian or Alaska Native000
Asian112
Native Hawaiian or Other Pacific Islander000
Black or African American011
White10515
More than one race000
Unknown or Not Reported033
Region of Enrollment
Region of Enrollment(Participants)Cohort 1 - Relapse SubjectsCohort 2 - Refractory SubjectsTotal
United States9615
United Kingdom246
08

Study locations

7 sites
  • Research Site
    Los Angeles, California 90095, United States
  • Research Site
    Atlanta, Georgia 30322, United States
  • Research Site
    New York, New York 10021, United States
  • Research Site
    Columbus, Ohio 43210, United States
  • Research Site
    Houston, Texas 77030, United States
  • Research Site
    Leicester, LE1 7RH, United Kingdom
  • Research Site
    Plymouth, PL6 8DH, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: htttps://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please refer to our disclosure commitment at: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. URL:

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2014 to primary completion in Jun 2020, 70 months.

Results were first posted in Jul 2020, the month primary completion was reached.

Of 84 industry-sponsored phase 1 interventional studies under Lymphoma, Large B-Cell, Diffuse, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 71. This study's 70 months is above that.

Counting every sponsor, half of 195 studies reached it within 53 months; a quarter within 35 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 10, 2014
First posted
Apr 14, 2014
StartActual
Aug 7, 2014
Primary completionActual
Jun 30, 2020
CompletionActual
Oct 4, 2024
Results first posted
Jul 29, 2020
Last update
Dec 20, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 20, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02112526
Lead sponsor
Acerta Pharma BV
Responsible party
Sponsor
First posted
Apr 14, 2014
Start date
Aug 7, 2014
Primary completion
Jun 30, 2020
Completion
Oct 4, 2024
Results posted
Jul 29, 2020
Last update
Dec 20, 2024

Study contacts

AstraZeneca Clinical Trials
study director · 1-877-240-9479; information.center@astrazeneca.com

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Acalabrutinib

Start the discussion